US OptionsDetailed Quotes

TWST240719P52500

Watchlist

1.11
-0.07-5.93%

15min DelayClose Jul 19 15:54 ET

1.11High1.11Low

Twist Bioscience Stock Discussion

ClydePeternuts

Jul 17 03:06

Cathie Wood and Ark Invest's trade activity from 2024/07/16

Buys🟢\\ $Beam Therapeutics(BEAM.US)$ $Oklo Inc(OKLO.US)$
Sells🔴\\ $Zoom Video Communications(ZM.US)$ $Trimble(TRMB.US)$ $Twist Bioscience(TWST.US)$ $UiPath(PATH.US)$

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics(CRSP.US)$ , $Intellia Therapeutics(NTLA.US)$ , $Beam Therapeutics(BEAM.US)$ , $Verve Therapeutics(VERV.US)$ , $Editas Medicine(EDIT.US)$
• Creating Therapies | $Prime Medicine(PRME.US)$ , $Sana Biotechnology(SANA.US)$
• Building DNA | $Twist Bioscience(TWST.US)$ , $Ginkgo Bioworks(DNA.US)$ , $Pacific Biosciences of California(PACB.US)$ , $Illumina(ILMN.US)$
• Dis...

Moomoo AI

Jan 5 13:12

Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.

Twist Bioscience Corporation (NASDAQ:TWST) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Moomoo AI

Dec 17, 2023 09:14

Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.

Companies Like Twist Bioscience (NASDAQ:TWST) Are In A Position To Invest In Growth

Moomoo AI

Nov 12, 2023 07:08

Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.

Shareholders in Twist Bioscience (NASDAQ:TWST) Have Lost 84%, as Stock Drops 9.6% This Past Week

Trytosaveabit

Oct 5, 2023 07:06

News

$Twist Bioscience(TWST.US)$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration